Merck (MRK) Construction in Progress (2009 - 2025)

Merck (MRK) posted quarterly Construction in Progress of $9.2 billion for Q4 2025, up 14.8% YoY from $8.0 billion in Q4 2024, and up 14.8% sequentially from $8.0 billion in Q4 2024.

Merck (MRK) Construction in Progress (2009 - 2025) Analysis & Trends

Merck has disclosed Construction in Progress across 17 years of filings, most recently posting $9.2 billion for Q4 2025.

  • In Q4 2025, Construction in Progress rose 14.8% year-over-year to $9.2 billion; the TTM figure through Dec 2025 stood at $9.2 billion (up 14.8% YoY), while the FY2025 annual figure was $9.2 billion, up 14.8% from the prior year.
  • Construction in Progress grew to $9.2 billion in Q4 2025, from $8.0 billion in the prior quarter.
  • Over the last five years, Construction in Progress for MRK reached as high as $9.2 billion in Q4 2022 and fell as low as $8.0 billion in Q4 2024.
  • The 5-year median for Construction in Progress is $8.3 billion (2021), against an average of $8.6 billion.
  • Annual changes were most pronounced in 2021 — Construction in Progress rose 19.3% — and 2023, when it retreated 10.06%.
  • A 5-year view of Construction in Progress shows it stood at $8.3 billion in 2021, then increased by 10.5% to $9.2 billion in 2022, then retreated by 10.06% to $8.3 billion in 2023, then retreated by 3.36% to $8.0 billion in 2024, then increased by 14.8% to $9.2 billion in 2025.
  • According to Business Quant data, Construction in Progress over the past three periods registered $9.2 billion, $8.0 billion, and $8.3 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn -
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 9.17 Bn
Dec 31, 2024 7.98 Bn
Dec 31, 2023 8.26 Bn
Dec 31, 2022 9.19 Bn
Dec 31, 2021 8.31 Bn
Dec 31, 2020 6.97 Bn
Dec 31, 2019 5.01 Bn
Dec 31, 2018 3.36 Bn
Dec 31, 2017 2.30 Bn
Dec 31, 2016 1.87 Bn
Dec 31, 2015 1.53 Bn
Dec 31, 2014 1.45 Bn
Dec 31, 2013 1.81 Bn
Dec 31, 2012 2.44 Bn
Dec 31, 2011 2.20 Bn
Dec 31, 2010 2.07 Bn
Dec 31, 2009 1.82 Bn